| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
61 |
| Employees |
450 |
| Revenues (TTM) (Millions $) |
113 |
| Net Income (TTM) (Millions $) |
-255 |
| Cash Flow (TTM) (Millions $) |
-393 |
| Capital Exp. (TTM) (Millions $) |
5 |
Business Description
Acceleron Pharma Inc.
is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines to treat serious and rare diseases.
The company was founded in 2003 and is headquartered in Cambridge, Massachusetts, with other offices located in Toronto, Canada, and Munich, Germany.
The company's main focus is in the field of TGF-e superfamily proteins, which play a vital role in regulating cell growth and differentiation.
Acceleron Pharma is a leader in the research of these proteins, and their work has resulted in the development of a number of investigational drugs that target different disorders.
Currently, Acceleron Pharma's most advanced drug candidate is luspatercept, which is being developed in collaboration with Celgene Corporation.
Luspatercept is a fusion protein that targets the TGF-e protein family and is currently being studied for the treatment of myelodysplastic syndromes (MDS) and beta-thalassemia.
Other key drug candidates being developed by the company include sotatercept, which is being studied for the treatment of pulmonary arterial hypertension, and ACE-083, a muscle-targeting agent being developed for the treatment of several neuromuscular conditions.
Acceleron Pharma has a strong pipeline of drug candidates, with a focus on rare and serious diseases, and has established collaborations with leading pharmaceutical companies such as Celgene, Shire and Biogen.
The company is committed to bringing new therapies to patients with rare diseases, which have very limited treatment options, and has made significant progress in this area.
Company Address: 128 Sidney Street Cambridge 2139 MA
Company Phone Number: 649-9200 Stock Exchange / Ticker: NASDAQ XLRN
|
%
2.22%